Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD

  • Joshua L. Rein
    Address for Correspondence: Joshua L. Rein, DO, Division of Nephrology, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Pl, Box 1243, New York, NY 10029.
    Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
    Search for articles by this author
  • Christina M. Wyatt
    Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
    Search for articles by this author
Published:August 12, 2017DOI:
      Marijuana is the most commonly used recreational drug in the United States, and legal recreational and medicinal use has gained public acceptance during the last decade. Twenty-nine US states have established medical marijuana programs, 8 of which have also legalized recreational marijuana, and Canada is expected to legalize recreational marijuana in 2018. Advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) are chronic conditions with significant associated morbidity and mortality. Patients experience substantial symptom burden that is frequently undertreated due to adverse medication side effects. This article reviews the available evidence for the use of medical marijuana to manage chronic pain, nausea/vomiting, anorexia/cachexia, and pruritus, all of which are frequently reported by patients with advanced CKD or ESRD. Potential adverse health effects of medical and recreational marijuana use are also discussed. Regardless of personal, social, and political beliefs, marijuana use is becoming mainstream, and nephrologists should be aware of the potential impact on our patient population. Further research is warranted to investigate the renal endocannabinoid system, the impact of marijuana use on kidney disease outcomes, and the risks and benefits of medical marijuana use on symptoms of advanced CKD and ESRD.

      Index Words

      To read this article in full you will need to make a payment


      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Saran R.
        • Li Y.
        • Robinson B.
        • et al.
        US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States.
        Am J Kidney Dis. 2015; 66: S1-S306
        • Ligresti A.
        • De Petrocellis L.
        • Di Marzo V.
        From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology.
        Physiol Rev. 2016; 96: 1593-1659
        • Maccarrone M.
        • Bab I.
        • Bíró T.
        • et al.
        Endocannabinoid signaling at the periphery: 50 years after THC.
        Trends Pharmacol Sci. 2015; 36: 277-296
        • Tam J.
        The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases.
        J Basic Clin Physiol Pharmacol. 2016; 27: 267-276
        • Jourdan T.
        • Szanda G.
        • Rosenberg A.Z.
        • et al.
        Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy.
        Proc Natl Acad Sci U S A. 2014; 111: E5420-E5428
        • Barutta F.
        • Corbelli A.
        • Mastrocola R.
        • et al.
        Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy.
        Diabetes. 2010; 59: 1046-1054
        • Lecru L.
        • Desterke C.
        • Grassin-Delyle S.
        • et al.
        Cannabinoid receptor 1 is a major mediator of renal fibrosis.
        Kidney Int. 2015; 88: 72-84
        • Barutta F.
        • Piscitelli F.
        • Pinach S.
        • et al.
        Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.
        Diabetes. 2011; 60: 2386-2396
        • Barutta F.
        • Grimaldi S.
        • Franco I.
        • et al.
        Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice.
        Kidney Int. 2014; 86: 979-990
        • Paronis C.A.
        • Thakur G.A.
        • Bajaj S.
        • et al.
        Diuretic effects of cannabinoids.
        J Pharmacol Exp Ther. 2013; 344: 8-14
        • Silva G.B.
        • Atchison D.K.
        • Juncos L.I.
        • García N.H.
        Anandamide inhibits transport-related oxygen consumption in the loop of Henle by activating CB1 receptors.
        Am J Physiol Renal Physiol. 2013; 304: F376-F381
        • Vidot D.C.
        • Prado G.
        • Hlaing W.M.
        • Florez H.J.
        • Arheart K.L.
        • Messiah S.E.
        Metabolic syndrome among marijuana users in the United States: an analysis of National Health and Nutrition Examination Survey data.
        Am J Med. 2016; 129: 173-179
        • Waterreus A.
        • Di Prinzio P.
        • Watts G.F.
        • Castle D.
        • Galletly C.
        • Morgan V.A.
        Metabolic syndrome in people with a psychotic illness: is cannabis protective?.
        Psychol Med. 2016; 46: 1651-1662
        • Rajavashisth T.B.
        • Shaheen M.
        • Norris K.C.
        • et al.
        Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III.
        BMJ Open. 2012; 2: e000494
        • Vupputuri S.
        • Batuman V.
        • Muntner P.
        • et al.
        The risk for mild kidney function decline associated with illicit drug use among hypertensive men.
        Am J Kidney Dis. 2004; 43: 629-635
        • Sommer G.L.
        • Schmid R.
        • Lubec G.
        Drug addicts and renal lesions.
        Drug Alcohol Depend. 1985; 16: 287-289
        • Cadman P.E.
        Hypophosphatemia in users of cannabis.
        Am J Kidney Dis. 2017; 69: 152-155
        • Ford B.M.
        • Tai S.
        • Fantegrossi W.E.
        • Prather P.L.
        Synthetic pot: not your grandfather's marijuana.
        Trends Pharmacol Sci. 2017; 38: 257-276
        • Bhanushali G.K.
        • Jain G.
        • Fatima H.
        • Leisch L.J.
        • Thornley-Brown D.
        AKI associated with synthetic cannabinoids: a case series.
        Clin J Am Soc Nephrol. 2013; 8: 523-526
        • Centers for Disease Control and Prevention (CDC)
        Acute kidney injury associated with synthetic cannabinoid use–multiple states, 2012.
        MMWR Morb Mortal Wkly Rep. 2013; 62: 93-98
        • Buser G.L.
        • Gerona R.R.
        • Horowitz B.Z.
        • et al.
        Acute kidney injury associated with smoking synthetic cannabinoid.
        Clin Toxicol. 2014; 52: 664-673
        • Pendergraft 3rd, W.F.
        • Herlitz L.C.
        • Thornley-Brown D.
        • Rosner M.
        • Niles J.L.
        Nephrotoxic effects of common and emerging drugs of abuse.
        Clin J Am Soc Nephrol. 2014; 9: 1996-2005
        • Luciano R.L.
        • Perazella M.A.
        Nephrotoxic effects of designer drugs: synthetic is not better!.
        Nat Rev Nephrol. 2014; 10: 314-324
        • Nanavati A.
        • Herlitz L.C.
        Tubulointerstitial injury and drugs of abuse.
        Adv Chronic Kidney Dis. 2017; 24: 80-85
        • Davison S.N.
        • Davison J.S.
        Is there a legitimate role for the therapeutic use of cannabinoids for symptom management in chronic kidney disease?.
        J Pain Symptom Manage. 2011; 41: 768-778
        • Murtagh F.E.
        • Addington-Hall J.
        • Higginson I.J.
        The prevalence of symptoms in end-stage renal disease: a systematic review.
        Adv Chronic Kidney Dis. 2007; 14: 82-99
        • Osborn L.A.
        • Lauritsen K.J.
        • Cross N.
        • et al.
        Self-medication of somatic and psychiatric conditions using botanical marijuana.
        J Psychoactive Drugs. 2015; 47: 345-350
        • National Academies of Sciences, Engineering, and Medicine
        The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.
        The National Academies Press, Washington, DC2017
        • Gruber S.A.
        • Sagar K.A.
        • Dahlgren M.K.
        • Racine M.T.
        • Smith R.T.
        • Lukas S.E.
        Splendor in the grass? A pilot study assessing the impact of medical marijuana on executive function.
        Front Pharmacol. 2016; 7: 355
        • Cooper B.A.
        • Branley P.
        • Bulfone L.
        • et al.
        A randomized, controlled trial of early versus late initiation of dialysis.
        N Engl J Med. 2010; 363: 609-619
        • Harris A.
        • Cooper B.A.
        • Li J.J.
        • et al.
        Cost-effectiveness of initiating dialysis early: a randomized controlled trial.
        Am J Kidney Dis. 2011; 57: 707-715
        • Koncicki H.M.
        • Unruh M.
        • Schell J.O.
        Pain management in CKD: a guide for nephrology providers.
        Am J Kidney Dis. 2017; 69: 451-460
        • Krishnan A.V.
        • Kiernan M.C.
        Uremic neuropathy: clinical features and new pathophysiological insights.
        Muscle Nerve. 2007; 35: 273-290
        • Shi Y.
        Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever.
        Drug Alcohol Depend. 2017; 173: 144-150
        • Bachhuber M.A.
        • Saloner B.
        • Cunningham C.O.
        • Barry C.L.
        Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.
        JAMA Intern Med. 2014; 174: 1668-1673
        • Hurd Y.L.
        Cannabidiol: swinging the marijuana pendulum from ‘weed’ to medication to treat the opioid epidemic.
        Trends Neurosci. 2017; 40: 124-127
        • Ifudu O.
        • Dawood M.
        • Homel P.
        • Friedman E.A.
        Timing of initiation of uremia therapy and survival in patients with progressive renal disease.
        Am J Nephrol. 1998; 18: 193-198
        • Sallan S.E.
        • Zinberg N.E.
        • Frei 3rd, E.
        Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.
        N Engl J Med. 1975; 293: 795-797
        • Whiting P.F.
        • Wolff R.F.
        • Deshpande S.
        • et al.
        Cannabinoids for medical use: a systematic review and meta-analysis.
        JAMA. 2015; 313: 2456-2473
        • Ikizler T.A.
        • Cano N.J.
        • Franch H.
        • et al.
        Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism.
        Kidney Int. 2013; 84: 1096-1107
        • Combs S.A.
        • Teixeira J.P.
        • Germain M.J.
        Pruritus in kidney disease.
        Semin Nephrol. 2015; 35: 383-391
        • Schlosburg J.E.
        • O'Neal S.T.
        • Conrad D.H.
        • Lichtman A.H.
        CB1 receptors mediate Rimonabant-induced pruritic responses in mice: investigation of locus of action.
        Psychopharmacology. 2011; 216: 323-331
        • Szepietowski J.C.
        • Reich A.
        • Szepietowski T.
        Emollients with endocannabinoids in the treatment of uremic pruritus: discussion of the therapeutic options.
        Ther Apher Dial. 2005; 9: 277-279
      1. Suitability for Organ Transplant, Medical Cannabis, RCW 69.51A.110, 2011 c 181 § 408. Accessed April 20, 2017.

        • Greenan G.
        • Ahmad S.B.
        • Anders M.G.
        • Leeser A.
        • Bromberg J.S.
        • Niederhaus S.V.
        Recreational marijuana use is not associated with worse outcomes after renal transplantation.
        Clin Transplant. 2016; 30: 1340-1346
        • Jaeger W.
        • Benet L.Z.
        • Bornheim L.M.
        Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes.
        Xenobiotica. 1996; 26: 275-284
        • Sido J.M.
        • Nagarkatti P.S.
        • Nagarkatti M.
        Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells.
        J Leukoc Biol. 2015; 98: 435-447
        • Utomo W.K.
        • de Vries M.
        • Braat H.
        • et al.
        Modulation of human peripheral blood mononuclear cell signaling by medicinal cannabinoids.
        Front Mol Neurosci. 2017; 10: 14
        • Marks W.H.
        • Florence L.
        • Lieberman J.
        • et al.
        Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient.
        Transplantation. 1996; 61: 1771-1774
        • Vethanayagam D.
        • Pugsley S.
        • Dunn E.J.
        • Russell D.
        • Kay J.M.
        • Allen C.
        Exogenous lipid pneumonia related to smoking weed oil following cadaveric renal transplantation.
        Can Respir J. 2000; 7: 338-342
        • Liebman S.E.
        • Lamontagne S.P.
        • Huang L.S.
        • Messing S.
        • Bushinsky D.A.
        Smoking in dialysis patients: a systematic review and meta-analysis of mortality and cardiovascular morbidity.
        Am J Kidney Dis. 2011; 58: 257-265
        • Sarafian T.A.
        • Magallanes J.A.
        • Shau H.
        • Tashkin D.
        • Roth M.D.
        Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids.
        Am J Respir Cell Mol Biol. 1999; 20: 1286-1293
        • Tashkin D.P.
        Effects of marijuana smoking on the lung.
        Ann Am Thorac Soc. 2013; 10: 239-247
        • Pletcher M.J.
        • Vittinghoff E.
        • Kalhan R.
        • et al.
        Association between marijuana exposure and pulmonary function over 20 years.
        JAMA. 2012; 307: 173-181
        • Wang X.
        • Derakhshandeh R.
        • Liu J.
        • et al.
        One minute of marijuana secondhand smoke exposure substantially impairs vascular endothelial function.
        J Am Heart Assoc. 2016; 5: e003858
        • Alshaarawy O.
        • Elbaz H.A.
        Cannabis use and blood pressure levels: United States National Health and Nutrition Examination Survey, 2005-2012.
        J Hypertens. 2016; 34: 1507-1512
        • Bai Q.
        • Zhang J.
        • Zhang A.H.
        • et al.
        Role of arachidonoylethanolamine in blood pressure regulation in volume-resistant patients on peritoneal dialysis.
        Int Urol Nephrol. 2012; 44: 1855-1860
        • Jouanjus E.
        • Lapeyre-Mestre M.
        • Micallef J.
        French Association of the Regional Abuse and Dependence Monitoring Centres (CEIP-A) Working Group on Cannabis Complications. Cannabis use: signal of increasing risk of serious cardiovascular disorders.
        J Am Heart Assoc. 2014; 3: e000638
        • Rumalla K.
        • Reddy A.Y.
        • Mittal M.K.
        Recreational marijuana use and acute ischemic stroke: a population-based analysis of hospitalized patients in the United States.
        J Neurol Sci. 2016; 364: 191-196
        • Mittleman M.A.
        • Lewis R.A.
        • Maclure M.
        • Sherwood J.B.
        • Muller J.E.
        Triggering myocardial infarction by marijuana.
        Circulation. 2001; 103: 2805-2809
        • Lorenz D.R.
        • Dutta A.
        • Mukerji S.S.
        • Holman A.
        • Uno H.
        • Gabuzda D.
        Marijuana use impacts midlife cardiovascular events in HIV-infected men.
        Clin Infect Dis. 2017; 65: 626-635
        • Reis J.P.
        • Auer R.
        • Bancks M.P.
        • et al.
        Cumulative lifetime marijuana use and incident cardiovascular disease in middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) Study.
        Am J Public Health. 2017; 107: 601-606
        • Meier M.H.
        • Caspi A.
        • Cerdá M.
        • et al.
        Associations between cannabis use and physical health problems in early midlife: a longitudinal comparison of persistent cannabis vs tobacco users.
        JAMA Psychiatry. 2016; 73: 731-740
        • Drew D.A.
        • Weiner D.E.
        • Tighiouart H.
        • et al.
        Cognitive decline and its risk factors in prevalent hemodialysis patients.
        Am J Kidney Dis. 2017; 69: 780-787
        • O'Lone E.
        • Connors M.
        • Masson P.
        • et al.
        Cognition in people with end-stage kidney disease treated with hemodialysis: a systematic review and meta-analysis.
        Am J Kidney Dis. 2016; 67: 925-935
        • Broyd S.J.
        • van Hell H.H.
        • Beale C.
        • Yücel M.
        • Solowij N.
        Acute and chronic effects of cannabinoids on human cognition-a systematic review.
        Biol Psychiatry. 2016; 79: 557-567
        • Bilkei-Gorzo A.
        • Albayram O.
        • Draffehn A.
        • et al.
        A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice.
        Nat Med. 2017; 23: 782-787